Wintest
6721
Ridge-i
5572
River Eletec
6666
Forside
2330
D. Western Therapeutics Institute
4576
(Q2)May 31, 2024 | (Q1)Feb 29, 2024 | (FY)Nov 30, 2023 | (Q4)Nov 30, 2023 | (Q3)Aug 31, 2023 | (Q2)May 31, 2023 | (Q1)Feb 28, 2023 | (FY)Nov 30, 2022 | (Q4)Nov 30, 2022 | (Q3)Aug 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.20%1.25B | 0.06%1.23B | 4.37%4.97B | 2.86%1.24B | 4.84%1.24B | 5.93%1.27B | 3.85%1.23B | -1.23%4.76B | 0.89%1.2B | -2.42%1.18B |
Cost of revenue | 0.71%952.38M | -3.48%930.78M | 6.12%3.81B | 2.50%941.43M | 4.21%961.84M | 6.95%945.64M | 11.12%964.32M | 1.91%3.59B | 4.66%918.44M | 1.61%922.95M |
Gross profit | -6.77%302.07M | 13.15%295.15M | -0.99%1.16B | 4.03%296.33M | 7.07%277.59M | 3.08%324.02M | -16.38%260.85M | -9.78%1.17B | -9.60%284.86M | -14.50%259.27M |
Operating expense | -3.31%141.1M | -9.94%142.09M | -2.30%584.34M | -5.18%140.83M | -6.10%139.82M | -3.23%145.92M | 5.25%157.76M | 7.58%598.1M | 7.14%148.52M | 4.80%148.91M |
Operating profit | -9.62%160.97M | 48.47%153.06M | 0.38%574.46M | 14.05%155.5M | 24.84%137.77M | 8.90%178.1M | -36.39%103.09M | -22.81%572.3M | -22.74%136.34M | -31.52%110.36M |
Net non-operating interest income (expenses) | 12.48%-7.55M | 8.89%-7.98M | 9.74%-33.81M | 12.49%-7.95M | 10.87%-8.46M | 9.39%-8.63M | 6.28%-8.76M | -3.62%-37.46M | 2.96%-9.09M | -1.10%-9.5M |
Non-operating interest income | 151.79%141K | --0 | 87.18%219K | 175.86%160K | 100.00%2K | -1.75%56K | 0.00%1K | 0.00%117K | 0.00%58K | 0.00%1K |
Non-operating interest expense | -11.42%7.69M | -8.90%7.98M | -9.44%34.03M | -11.29%8.11M | -10.86%8.47M | -9.34%8.68M | -6.28%8.76M | 3.61%37.57M | -2.94%9.15M | 1.10%9.5M |
Net investment income | 0 | 95.41%11.55M | -0.91%38.96M | 0 | 5.32%33.05M | 0 | -25.42%5.91M | 43.23%39.31M | 0 | 32.63%31.38M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | -3.89M | 213K | -129K | |||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -125.53%-4.17M | 204K | 171.50%31.04M | 114.45%201K | 348.19%14.51M | 145.14%16.33M | 0 | -474.87%-43.42M | -371.15%-1.39M | -158.69%-5.85M |
Less:Other special charges | --4.17M | ---204K | -171.50%-31.04M | -114.45%-201K | -348.19%-14.51M | ---- | ---- | 474.87%43.42M | 371.15%1.39M | 158.69%5.85M |
Other non-operating income (expenses) | 238.48%1.29M | -53.27%1.6M | 46.97%5.6M | 35.21%1.08M | 9.04%712K | -70.86%382K | 227.46%3.42M | 296.85%3.81M | 259.92%798K | 175.49%653K |
Income before tax | -19.14%150.55M | 52.83%158.43M | 16.13%616.24M | 17.31%148.83M | 39.91%177.57M | 61.63%186.19M | -35.88%103.66M | -28.51%530.66M | -24.09%126.87M | -31.21%126.92M |
Income tax | -22.75%48.59M | 54.02%54.36M | 20.19%203.23M | 24.44%44.12M | 43.75%60.92M | 66.43%62.9M | -34.00%35.29M | -28.21%169.1M | -24.73%35.46M | -30.43%42.38M |
Net income | -17.30%101.96M | 52.22%104.07M | 14.23%413.01M | 14.54%104.71M | 37.98%116.65M | 59.29%123.29M | -36.82%68.37M | -28.66%361.56M | -23.84%91.41M | -31.59%84.54M |
Net income continuous operations | -17.30%101.96M | 52.22%104.07M | 14.23%413.01M | 14.54%104.7M | 37.98%116.65M | 59.29%123.29M | -36.82%68.37M | -28.66%361.56M | -23.84%91.41M | -31.60%84.54M |
Noncontrolling interests | -4.28%313K | -63.84%162K | -32.27%808K | -90.70%57K | -110.67%-24K | 35.68%327K | 292.98%448K | 267.08%1.19M | 185.12%613K | 0.00%225K |
Net income attributable to the company | -17.34%101.64M | 52.98%103.91M | 14.38%412.2M | 15.25%104.65M | 38.37%116.67M | 59.36%122.96M | -37.16%67.92M | -28.85%360.37M | -24.21%90.8M | -31.65%84.32M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -17.34%101.64M | 52.98%103.91M | 14.38%412.2M | 15.25%104.65M | 38.37%116.67M | 59.36%122.96M | -37.16%67.92M | -28.85%360.37M | -24.21%90.8M | -31.65%84.32M |
Gross dividend payment | ||||||||||
Basic earnings per share | -17.38%17.16 | 53.01%17.55 | 15.00%69.61 | 15.57%17.67 | 39.22%19.7 | 60.39%20.77 | -36.77%11.47 | -28.78%60.53 | -23.97%15.29 | -31.64%14.15 |
Diluted earnings per share | -17.37%17.16 | 53.01%17.55 | 15.00%69.61 | 15.57%17.67 | 39.23%19.7 | 60.38%20.7664 | -36.77%11.47 | -28.78%60.53 | -23.95%15.29 | -31.65%14.1491 |
Dividend per share | 0 | 0 | 0.00%16 | 0.00%16 | 0 | 0 | 0 | 0.00%16 | 0.00%16 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |